{"id":"iiv4-and-ppv23","safety":{"commonSideEffects":[{"rate":"10-30","effect":"Injection site pain, erythema, or swelling"},{"rate":"5-15","effect":"Fever"},{"rate":"5-15","effect":"Myalgia or fatigue"},{"rate":"5-10","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"IIV4 (inactivated influenza vaccine, quadrivalent) contains inactivated influenza virus antigens from four strains, while PPV23 (pneumococcal polysaccharide vaccine) contains polysaccharide antigens from 23 pneumococcal serotypes. Both vaccines work by presenting these antigens to the immune system, triggering B and T cell responses that generate protective antibodies and cellular immunity against the respective pathogens.","oneSentence":"IIV4 and PPV23 are inactivated influenza and pneumococcal vaccines that stimulate the immune system to produce antibodies against influenza virus strains and Streptococcus pneumoniae serotypes.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:40:35.609Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of seasonal influenza (IIV4)"},{"name":"Prevention of pneumococcal disease caused by Streptococcus pneumoniae serotypes in PPV23"}]},"trialDetails":[{"nctId":"NCT05480436","phase":"PHASE4","title":"Immunogenicity and Safety of BBIBP-Corv Coadministered With PPV23 and IIV4 in Hemodialysis Population","status":"UNKNOWN","sponsor":"China National Biotec Group Company Limited","startDate":"2022-08-05","conditions":"Hemolysis, COVID-19","enrollment":1200},{"nctId":"NCT04559204","phase":"PHASE4","title":"Evaluation of Safety and Immunogenicity of Combined Immunization of PPV23 and IIV4","status":"COMPLETED","sponsor":"China National Biotec Group Company Limited","startDate":"2020-09-11","conditions":"Influenza, Human, Pneumonia, Pneumococcal","enrollment":1224},{"nctId":"NCT04790851","phase":"PHASE4","title":"Evaluation of Immunogenicity and Safety of Combined Immunization of COVID-19 Vaccine (Produced in Beijing) and PPV23 / IIV4","status":"COMPLETED","sponsor":"China National Biotec Group Company Limited","startDate":"2021-03-10","conditions":"Influenza, Human, Pneumonia, Pneumococcal, Covid19","enrollment":1133},{"nctId":"NCT05079152","phase":"PHASE4","title":"Evaluation of Immunogenicity and Safety of Combined Immunization of COVAX (Produced in Wuhan) and PPV23 / IIV4","status":"UNKNOWN","sponsor":"China National Biotec Group Company Limited","startDate":"2021-05-06","conditions":"Influenza, Human, Pneumonia, Pneumococcal, COVID-19 Pneumonia","enrollment":1404}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"IIV4 and PPV23","genericName":"IIV4 and PPV23","companyName":"China National Biotec Group Company Limited","companyId":"china-national-biotec-group-company-limited","modality":"Biologic","firstApprovalDate":"","aiSummary":"IIV4 and PPV23 are inactivated influenza and pneumococcal vaccines that stimulate the immune system to produce antibodies against influenza virus strains and Streptococcus pneumoniae serotypes. Used for Prevention of seasonal influenza (IIV4), Prevention of pneumococcal disease caused by Streptococcus pneumoniae serotypes in PPV23.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}